Early-Stage cancer drug trial halted after only 3 patients
Disease control
Terminated
This early-phase study tested a new drug called AXN-2510 in 3 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to find safe dosing and understand side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Axion Bio, Inc • Aim: Disease control
Last updated May 26, 2026 12:04 UTC